Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Cited by (1,005)

Items 601–700 of 1,005

1. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine
   Xia Xie, Bo Tang, Jianyun Zhou, Qing Gao, Peng-Bing Zhang · 2013 · Oncology Reports
2. Targeting Aberrant PI3K/Akt Activation by PI103 Restores Sensitivity to TRAIL-Induced Apoptosis in Neuroblastoma
   Daniela Opel, Ivonne Naumann, Maxi Schneider, Daniela Bertele, Klaus‐Michael Debatin, Simone Fulda · 2011 · Clinical Cancer Research
3. New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
   Vandana Gupta Abramson, Carlos L. Arteaga · 2011 · Clinical Cancer Research
4. Transferrin receptor-mediated liposomal drug delivery: recent trends in targeted therapy of cancer
   Solmaz Mojarad-Jabali, Somayeh Mahdinloo, Masoud Farshbaf, Muhammad Sarfraz, Yousef Fatahi, Fatemeh Atyabi, Hadi Valizadeh · 2022 · Expert Opinion on Drug Delivery
5. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors
   Marta Dueñas, Mónica Martínez‐Fernández, Ramón García‐Escudero, Felipe Villacampa, Miriam Marqués, Cristina Sáiz-Ladera, José Manuel Duarte, Victor Martínez, Ma José Gómez, Ma Luisa Martı́n et al. · 2013 · Molecular Carcinogenesis
6. IL-6 and ICOS Antagonize Bim and Promote Regulatory T Cell Accrual with Age
   Jana L. Raynor, Rebekah A. Karns, Maha Almanan, Kun‐Po Li, Senad Divanovic, Claire Anne Chougnet, David A. Hildeman · 2015 · The Journal of Immunology
7. Breast Tumors with Elevated Expression of 1q Candidate Genes Confer Poor Clinical Outcome and Sensitivity to Ras/PI3K Inhibition
   Muthulakshmi Muthuswami, Vignesh Ramesh, Saikat Banerjee, Soundara Viveka Thangaraj, Jayaprakash Periasamy, Divya Bhaskar Rao, Georgina D. Barnabas, Swetha Raghavan, Kumaresan Ganesan · 2013 · PLoS ONE
8. Involvement of the phosphoinositide 3-kinase/Akt pathway in apoptosis induced by capsaicin in the human pancreatic cancer cell line PANC-1
   JIAN-HONG ZHANG, FU-JI LAI, Hui Chen, Luo Jiang, Riyuan Zhang, Heqi Bu, Zhaohong Wang, HONG-HAI LIN, Shengzhang Lin · 2012 · Oncology Letters
9. Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor
   Robert G. Mallon, Irwin J. Hollander, Larry R. Feldberg, Judy Lucas, Veronica Soloveva, Aranapakam M. Venkatesan, Christoph M. Dehnhardt, Efren Delos Santos, Zecheng Chen, Osvaldo dos Santos et al. · 2010 · Molecular Cancer Therapeutics
10. Dormancy of Cancer Cells with Suppression of AKT Activity Contributes to Survival in Chronic Hypoxia
    Hiroko Endo, Hiroaki Okuyama, Masayuki Ohue, Masahiro Inoue · 2014 · PLoS ONE
11. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
    Wen‐Chi Yang, Sheng-Fung Lin · 2015 · BioMed Research International
12. Emerging roles of Nrf2 signal in non-small cell lung cancer
    Yijun Tian, Qian Liu, Xuelian He, Xun Yuan, Yuan Chen, Qian Chu, Kongming Wu · 2016 · Journal of Hematology & Oncology
13. Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells
    David H. Raulet, Assaf Marcus, Laurent Coscoy · 2017 · Immunological Reviews
14. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy
    Mai Badarni, Manu Prasad, Noa Balaban, Jonathan Zorea, Ksenia M. Yegodayev, Ben‐Zion Joshua, Anat Bahat Dinur, Reidar A. Grenman, Barak Rotblat, Limor Cohen et al. · 2019 · JCI Insight
15. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression
    Victor Chin Yong Ho, Tong Seng Lim, Justin Lee, Jeffrey D. Steinberg, Radosław Szmyd, Muly Tham, Jadegoud Yaligar, Philipp Kaldis, Jean‐Pierre Abastado, Valerie Chew · 2015 · Oncotarget
16. LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85
    Shuangbing Xu, Yan Li, Yanwei Lu, Jing Huang, Jinghua Ren, Sheng Zhang, Zhongyuan Yin, Kai Huang, Gang Wu, Kunyu Yang · 2018 · Cancer Letters
17. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
    Priyanka Singh, Veerandra Kumar, Sonu Kumar Gupta, Gudia Kumari, Malkhey Verma · 2021 · Medical Oncology
18. Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma
    Chenchen Zhu, Zhihao Xu, Tianjiao Zhang, Lili Qian, Weihua Xiao, Haiming Wei, Tengchuan Jin, Ying Yin Zhou · 2021 · Journal of Cancer
19. Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas
    Yu‐Chieh Su, Wei-Chang Lee, Chih-Chun Wang, Shyh‐An Yeh, Wenhui Chen, Po‐Jen Chen · 2022 · International Journal of Molecular Sciences
20. The Akt-associated microRNAs
    Min Xu, Yin‐Yuan Mo · 2012 · Cellular and Molecular Life Sciences
21. Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis
    Liang Weng, Atsushi Enomoto, Maki Takagishi, Naoya Asai, Masahide Takahashi · 2009 · Cancer Science
22. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
    Sara Alsterlind Hurvitz, Ondrej Kalous, Dylan F. Conklin, Amrita J. Desai, Judy Dering, Lee A. Anderson, Neil A. O’Brien, Teodora R. Kolarova, Richard S. Finn, Ronald Linnartz et al. · 2015 · Breast Cancer Research and Treatment
23. The molecular pathogenesis of small cell lung cancer
    Sandra P. D’Angelo, Maria Catherine Pietanza · 2010 · Cancer Biology & Therapy
24. Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer
    Ebubekir Dirican, Mustafa Akkіprіk, Ayşe Özer · 2016 · Tumor Biology
25. Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH2 Domains
    Mingzhen Zhang, Hyunbum Jang, Vadim Gaponenko, Ruth Nussinov · 2017 · Biophysical Journal
26. Correlation between microbes and colorectal cancer: tumor apoptosis is induced by sitosterols through promoting gut microbiota to produce short-chain fatty acids
    Hang Ma, Yang Yu, Meimei Wang, Zhaoxing Li, Heshan Xu, Tian Cheng, Jian Zhang, Xiaoli Ye, Xuegang Li · 2018 · APOPTOSIS
27. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem‐like phenotype through modulation of the PI3K/Akt/β‐catenin/CBP pathway
    Kaijie He, Tong Xu, Yucheng Xu, Alexander Ring, Michaël Kahn, Amir Goldkorn · 2013 · International Journal of Cancer
28. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway
    Pengfei Shi, Tao Yin, Feng Zhou, Pengfei Cui, Shanmiao Gou, Chunyou Wang · 2014 · BMC Cancer
29. miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma
    Chuyong Lin, Aibin Liu, Jinrong Zhu, Xin Zhang, Geyan Wu, Pengli Ren, Jueheng Wu, Mengfeng Li, Jun Li, Libing Song · 2014 · Nature Communications
30. Endogenous Angiogenesis Inhibitor Blocks Tumor Growth via Direct and Indirect Effects on Tumor Microenvironment
    Dimitra Bourboulia, Sandra Jensen-Taubman, Matthew Robert Rittler, Hui Han, Tania Chatterjee, Beiyang Wei, William George Stetler‐Stevenson · 2011 · American Journal Of Pathology
31. Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer
    James M. Cleary, Geoffrey Ira Shapiro · 2010 · Current Oncology Reports
32. Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer
    Tao Zuo, Ta-Ming Liu, Xun Lan, Yu‐I Weng, Rulong Z. Shen, Fei Gu, Yi‐Wen Huang, Sandya Liyanarachchi, Daniel E. Deatherage, Pei-Yin Hsu et al. · 2011 · Cancer Research
33. From procaspase‐8 to caspase‐8: Revisiting structural functions of caspase‐8
    Yang Zhao, Xin Sui, Hong Ren · 2010 · Journal of Cellular Physiology
34. BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomas
    Meng Dai, Jian-Jun Lu, Wei Guo, Wendan Yu, Qimin Wang, Ranran Tang, Zhipeng Tang, Yao Xiao, Zhenglin Li, Wei Sun et al. · 2015 · Oncotarget
35. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
    Gary Beale, Emma J. Haagensen, Huw D. Thomas, Lan-Zhen Wang, Charlotte Revill, Sara L. Payne, Bernard T. Golding, Ian Robert Hardcastle, David R. Newell, Roger J. Griffin et al. · 2016 · British Journal of Cancer
36. Recent advances in cancer metabolism: a technological perspective
    Yun Pyo Kang, Nathan P. Ward, Gina M. DeNicola · 2018 · Experimental & Molecular Medicine
37. Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein
    Ellen Preuß, Manuela Hugle, Romy Reimann, Marcel Schlecht, Simone Fulda · 2013 · Journal of Biological Chemistry
38. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts
    Michael McKenna, Sarah A. McGarrigle, Graham P. Pidgeon · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
39. Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome
    Juan Carlos López‐Gutiérrez, Rocío Lizarraga, Carlos Delgado, María José Martínez-Urrutia, Mercedes Díaz, Miriam Miguel‐Ferrero, Paloma Triana · 2019 · Journal of Pediatric and Adolescent Gynecology
40. The algal polysaccharide ulvan suppresses growth of hepatoma cells
    Chao Zhao, Guopeng Lin, Desheng Wu, Dan Liu, Lijun You, Petra Högger, Jesús Simal‐Gándara, Mingfu Wang, José Galberto Martins da Costa, Yoshinori Marunaka et al. · 2020 · Food Frontiers
41. Phosphorylated mTOR Expression is Associated with Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma
    Kotaro Hirashima, Yoshifumi Baba, Masayuki Watanabe, Ryu-ichi Karashima, Nobutaka Sato, Yu Imamura, Yukiharu Hiyoshi, Yohei Nagai, Naoko Hayashi, Ken-ichi Iyama et al. · 2010 · Annals of Surgical Oncology
42. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
    Rafael Bierig Erlich, Zoulika Kherrouche, Danny Rickwood, Liliana Endo‐Munoz, Sarina R. Cameron, Alison L. Dahler, Mehlika H. Hazar-Rethinam, Lilia Merida de Long, K Wooley, Alexander David Guminski et al. · 2011 · British Journal of Cancer
43. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma
    Yanjing Jia, Ze‐Bing Liu, W G Wang, Chuanyu Sun, Ping Wei, Ya‐Ling Yang, Mingjian James You, B H Yu, X Q Li, Xiang Zhou · 2017 · Leukemia
44. TUFT1 interacts with RABGAP1 and regulates mTORC1 signaling
    Natsumi Kawasaki, Kazunobu Isogaya, Shingo Dan, Takao Yamori, Hiroshi Takano, Ryoji Yao, Yasuyuki Morishita, Luna Taguchi, Masato Morikawa, Carl‐Henrik Heldin et al. · 2018 · Cell Discovery
45. RUNX2: A Master Bone Growth Regulator That May Be Involved in the DNA Damage Response
    Daniel Wysokiński, Elżbieta Pawłowska, Janusz Błasiak · 2015 · DNA and Cell Biology
46. Olive Oil‐derived Oleocanthal as Potent Inhibitor of Mammalian Target of Rapamycin: Biological Evaluation and Molecular Modeling Studies
    Mohammad A. Khanfar, Sanaa K. Bardaweel, Mohamed R. Akl, Khalid A. El Sayed · 2015 · Phytotherapy Research
47. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo
    Lova Segerström, Ninib Baryawno, Baldur Sveinbjørnsson, Malin Wickström, Lotta H. M. Elfman, Per Kogner, John Inge Johnsen · 2011 · International Journal of Cancer
48. Multifunctional targets of dietary polyphenols in disease: A case for the chemokine network and energy metabolism
    Jorge Joven, Anna Rull, Esther Rodríguez‐Gallego, Jordi Camps, Marta Riera-Borrull, Anna Hernández‐Aguilera, Vicente Martín-Paredero, Antonio Segura‐Carretero, Vicente Micol, Carlos Alonso‐Villaverde et al. · 2012 · Food and Chemical Toxicology
49. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation
    Tobias Ettl, Stephan Schwarz‐Furlan, Frank Haubner, Steffen Müller, Johannes Zenk, Martin Gosau, Torsten E. Reichert, Katharina Zeitler · 2012 · Oral Oncology
50. Dopamine, by Acting through Its D2 Receptor, Inhibits Insulin-Like Growth Factor-I (IGF-I)-Induced Gastric Cancer Cell Proliferation via Up-Regulation of Krüppel-Like Factor 4 through Down-Regulation of IGF-IR and AKT Phosphorylation
    Subhalakshmi Ganguly, Biswarup Basu, Saurav Shome, Tushar Jadhav, Sudipta Singha Roy, Jahar Majumdar, Partha Dasgupta, Sujit Basu · 2010 · American Journal Of Pathology
51. The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
    Carolina Simioni, Alberto Maria Martelli, Alice Cani, Rengül Çetin-Atalay, James Andrew McCubrey, Silvano Capitani, Luca Maria Neri · 2013 · Oncotarget
52. A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition
    Hai-Ling Margaret Cheng, Pixu Liu, Fan Zhang, Erbo Xu, Lynn Katherine Symonds, Carolynn E. Ohlson, Roderick Terry Bronson, Sauveur-Michel Maira, Emmanuelle di Tomaso, Jane Li et al. · 2013 · Cancer Research
53. AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-κB axis
    Bin Zheng, Geng Li, Li Zeng, Fangfang Liu, Qiaojia Huang · 2018 · Cellular Signalling
54. Anticancer effects and underlying mechanism of Colchicine on human gastric cancer cell lines in vitro and in vivo
    Tao� Zhang, Wei Chen, Xumian Jiang, Lei Liu, Kai Wei, Hansong Du, Hui Wang, Juan Li · 2018 · Bioscience Reports
55. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
    Robert Jr. Roskoski · 2021 · Pharmacological Research
56. PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma
    Tasuku Matsuoka, Masakazu Yashiro, Nobuaki Nishioka, Kosei Hirakawa, Kenneth Olden, John D. Roberts · 2012 · British Journal of Cancer
57. Cell cycle dependence on the mevalonate pathway: Role of cholesterol and non-sterol isoprenoids
    Miguel Angel Lasunción, Javier Martı́nez-Botas, Covadonga Martín-Sánchez, Rebeca Busto, Diego Gómez‐Coronado · 2021 · Biochemical Pharmacology
58. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis
    Wenting Mi, Qing Ye, Side Liu, Qing‐Bai She · 2015 · Oncotarget
59. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors
    Florian Ewald, Dominik Sebastian Nörz, Astrid Grottke, Bianca T. Hofmann, Björn Nashan, Manfred Jücker · 2014 · Investigational New Drugs
60. Targeting the PI3K Pathway for Cancer Therapy
    Navid Sadeghi, David E. Gerber · 2012 · Future Medicinal Chemistry
61. Small molecules targeting phosphoinositide 3-kinases
    Peng Wu, Yongzhou Hu · 2012 · MedChemComm
62. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation
    Justine Rudner, Carola-Ellen Ruiner, René Handrick, Hansjörg Eibl, Claus Belka, Verena Jendrossek · 2010 · Radiation Oncology
63. NF2/Merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations
    Rebecca Dunbar Schroeder, Laura S. Angelo, Razelle Kurzrock · 2013 · Oncotarget
64. Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice
    Maria E. Balasis, Kara D. Forinash, Y. Ann Chen, William J. Fulp, Domenico Coppola, Andrew D. Hamilton, Jin Quan Cheng, Saı̈d M. Sebti · 2011 · Clinical Cancer Research
65. Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway
    Xianjun Zhang, Hongyuan Yu, Yong-jian Cai, Mang Ke · 2016 · Oncotarget · Retracted
66. Trehalose Induces Autophagy Against Inflammation by Activating TFEB Signaling Pathway in Human Corneal Epithelial Cells Exposed to Hyperosmotic Stress
    Zhao Liu, Ding Chen, Xin Chen, Fang Bian, Wenjuan Qin, Ning Gao, Yangyan Xiao, Jinmiao Li, Stephen Carl Pflugfelder, De‐Quan Li · 2020 · Investigative Ophthalmology & Visual Science
67. Alterations in transcriptome and antioxidant activity of naturally aged mice exposed to selenium-rich rice
    Rui Zeng, Yuanke Liang, Muhammad Umer Farooq, Yujie Zhang, Hla Hla, Zhichen Tang, Tengda Zheng, Su Yang, Xiaoying Ye, Xiaomei Jia et al. · 2019 · Environmental Science and Pollution Research
68. Strategies to overcome drug resistance using SHP2 inhibitors
    Meng Liu, Shan Gao, Reham M. Elhassan, Xuben Hou, Hao Fang · 2021 · Acta Pharmaceutica Sinica B
69. The roles of glycolysis in osteosarcoma
    Zuxi Feng, Yanghuan Ou, Liang Hao · 2022 · Frontiers in Pharmacology
70. Potent antitumor activity of cabozantinib, a c‐ MET and VEGFR 2 inhibitor, in a colorectal cancer patient‐derived tumor explant model
    Eun‐Kee Song, WM. Tai, Wells A. Messersmith, Stacey M. Bagby, Alicia Purkey, Kevin S. Quackenbush, Todd M. Pitts, Guoliang Wang, Patrick Jud Blatchford, Rachel Yahn et al. · 2014 · International Journal of Cancer
71. Brain overgrowth in disorders of RTK–PI3K–AKT signaling: A mosaic of malformations
    Robert F. Hevner · 2014 · Seminars in Perinatology
72. Akt/protein kinase B in skeletal muscle physiology and pathology
    Miaozong Wu, Marco Falasca, Eric R. Blough · 2010 · Journal of Cellular Physiology
73. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway
    Candice Jackel‐Cram, Ling Qiao, Z. Xiang, Robert M. Brownlie, Yan Zhou, Lorne A. Babiuk, Qiang Liu · 2010 · Journal of General Virology
74. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors
    Emilie Clement, Hiroyuki Inuzuka, Naoe Taira Nihira, Wenyi Wei, Alex Toker · 2018 · Science Signaling
75. Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells
    Liyuan Mao, Qiongyun Chen, Ke Gong, Xiaolin Xu, Yurou Xie, Wenqing Zhang, Hanwei Cao, Tianhui Hu, Xiaoting Hong, Yan-yan Zhan · 2018 · Oncology Reports
76. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
    Foster, Paul, Yamaguchi, Kyoko, Hsu, Pin P., Qian, Fawn, Du, Xiangnan, Wu, Jianming, Won, Kwang-Ai, Yu, Peiwen, Jaeger, Christopher T., Zhang, Wentao et al. · 2015 · Molecular Cancer Therapeutics
77. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
    Peter Stephen Savas, Brett G.M. Hughes, Benjamin Solomon · 2013 · Europe PMC (PubMed Central)
78. Cell signaling pathways as molecular targets to eliminate AML stem cells
    Ana Carolina Rodrigues, Rafaela G.A. Costa, Suellen L. R. Silva, Ingrid R. S. B. Dias, Rosane B. Dias, Daniel Pereira Bezerra · 2021 · Critical Reviews in Oncology/Hematology
79. Binding of Galectin-3, a β-Galactoside-binding Lectin, to MUC1 Protein Enhances Phosphorylation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) and Akt, Promoting Tumor Cell Malignancy
    Yugo Mori, Kaoru Akita, Masakazu Yashiro, Tetsuji Sawada, Kosei Hirakawa, Takeomi Murata, Hiroshi Nakada · 2015 · Journal of Biological Chemistry
80. Nitroxoline induces apoptosis and slows glioma growth in vivo
    Jelena Lazović, Lea Guo, Jonathan K. Nakashima, Leili Mirsadraei, William H. Yong, Hyun J. Kim, Benjamin M. Ellingson, Hong Wu, Whitney B. Pope · 2014 · Neuro-Oncology
81. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors
    Matthew G. Fury, Eric Jeffrey Sherman, Sofia S. Haque, Susan H. Korte, Donna Lisa, Ronglai Shen, Nian Fen Wu, David G. Pfister · 2011 · Cancer Chemotherapy and Pharmacology
82. Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”
    Sreenath V. Sharma, Jeff Settleman · 2010 · Biochemical Pharmacology
83. Elaborate Ligand-Based Modeling Coupled with Multiple Linear Regression and k Nearest Neighbor QSAR Analyses Unveiled New Nanomolar mTOR Inhibitors
    Mohammad A. Khanfar, Mutasem O. Taha · 2013 · Journal of Chemical Information and Modeling
84. Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail
    Weijia Cai, Qing Ye, Qing‐Bai She · 2014 · Oncotarget
85. Molecular Aspects of Head and Neck Cancer Therapy
    Sidharth V. Puram, James William Rocco · 2015 · Hematology/Oncology Clinics of North America
86. Platelet-Derived Growth Factor Receptor Activation Promotes the Prodestructive Invadosome-Forming Phenotype of Synoviocytes from Patients with Rheumatoid Arthritis
    Martine Charbonneau, Roxane R. Lavoie, Annie Lauzier, Kelly Harper, Patrick P. McDonald, Claire M. Dubois · 2016 · The Journal of Immunology
87. DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer
    Yang Yang, Meihua Gao, Zhenhua Lin, Liyan Chen, Yu Tong Jin, Guang Zhu, Yixuan Wang, Tiefeng Jin · 2017 · Oncotarget
88. Molecularly Targeted Therapies in Multiple Myeloma
    Pilar de la Puente, Barbara Muz, Feda Azab, Micah John Luderer, Abdel Kareem Azab · 2014 · Leukemia Research and Treatment
89. Biological activities of [1,2,4]triazolo[1,5-a]pyrimidines and analogs
    Sérgio Pinheiro, Erick M.C. Pinheiro, Estela M.F. Muri, J. C. Pessôa, Mayara A. Cadorini, Sandro J. Greco · 2020 · Medicinal Chemistry Research
90. Beneficial effects of olive oil and Mediterranean diet on cancer physio-pathology and incidence
    Marta Farràs, Enrique Almanza‐Aguilera, Álvaro Hernáez, Núria Agustí, Josep Julve, Montserrat Fitó, Olga Castañer · 2020 · Seminars in Cancer Biology
91. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer
    Mohammed A. Aleskandarany, Emad A. Rakha, Mohamed A. H. Ahmed, Desmond George Powe, Ian Ogilvie Ellis, Andrew R. Green · 2010 · Breast Cancer Research and Treatment
92. Post-translational regulation of FOXO
    Qi Xie, Jing Chen, Zengqiang Yuan · 2012 · Acta Biochimica et Biophysica Sinica
93. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone
    Yuhuan Zheng, Jing Yang, Jianfei Qian, Liang Zhang, Yong Lu, Haiyan Li, Heather Yan Lin, Yongsheng Lan, Zhiqiang Liu, Jin He et al. · 2011 · Journal of Molecular Medicine
94. The role of obesity in gastrointestinal cancer: evidence and opinion
    Claire L. Donohoe, Naoimh J. O’Farrell, Suzanne L. Doyle, John Vincent Reynolds · 2013 · Therapeutic Advances in Gastroenterology
95. A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
    Shujie Yang, Xue Xiao, Xiangbing Meng, Kimberly Kay Leslie · 2011 · PLoS ONE
96. Fucosterol exhibits selective antitumor anticancer activity against HeLa human cervical cell line by inducing mitochondrial mediated apoptosis, cell cycle migration inhibition and downregulation of m-TOR/PI3K/Akt signalling pathway
    Hongye Jiang, Jie Li, Aiyue Chen, Yinguang Li, Meng Xia, Peng Guo, Shuzhong Yao, Shuqin Chen · 2018 · Oncology Letters · Retracted
97. An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial–mesenchymal transition and cancer stem cell expansion in human breast cancer cells
    Lin Yang, Siqi Han, Yong Jiang Sun · 2014 · Biochemical and Biophysical Research Communications
98. Quantitative fluorescent profiling of VEGFR s reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts
    P. I. Imoukhuede, Aleksander S. Popel · 2014 · Cancer Medicine
99. Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway
    SHREYASKUMAR R. PATEL · 2013 · Current Oncology Reports
100. The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer
     Μαρία Τράκα, Caroline A Spinks, Joanne F. Doleman, Antonietta Melchini, Richard Y. Ball, Robert Mills, Richard F. Mithen · 2010 · Molecular Cancer